CamBMT1: A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases (mets) for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy.
Authors
Baird, RGarcia-Corbacho, J
Ramenatte, N
Jonson, A
Ahmad, S
Smith, D
Qian, W
Kumar, S
Linossi, C
Matys, T
Graves, M
Jodrell, D
Caldas, C
Pacey, S
Whitfield, Gillian A
Chalmers, A
Jena, R
Price, S
Jefferies, S
Watts, C
Affiliation
Breast Cancer Research Unit, Addenbrookes Hospital Box 97, Cambridge Cancer Centre, CambridgeIssue Date
2016-10-01
Metadata
Show full item recordCitation
CamBMT1: A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases (mets) for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy. 2016, 27 (suppl 6):408TiP Annals of OncologyJournal
Annals of OncologyDOI
10.1093/annonc/mdw368.51Additional Links
https://academic.oup.com/annonc/article/2799147/CamBMT1:Type
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdw368.51